NRx Pharmaceuticals Inc. (NRXP)
NRx Pharmaceuticals Statistics
Share Statistics
NRx Pharmaceuticals has 16.92M shares outstanding. The number of shares has increased by 58.08% in one year.
| Shares Outstanding | 16.92M |
| Shares Change (YoY) | 58.08% |
| Shares Change (QoQ) | 39.87% |
| Owned by Institutions (%) | 0.03% |
| Shares Floating | 14.03M |
| Failed to Deliver (FTD) Shares | 9.58K |
| FTD / Avg. Volume | 1.47% |
Short Selling Information
The latest short interest is 682.66K, so 5.64% of the outstanding shares have been sold short.
| Short Interest | 682.66K |
| Short % of Shares Out | 5.64% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 4.8 |
Valuation Ratios
The PE ratio is -0.92 and the forward PE ratio is -118.33. NRx Pharmaceuticals's PEG ratio is 0.02.
| PE Ratio | -0.92 |
| Forward PE | -118.33 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | -1 |
| P/FCF Ratio | -2.18 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NRx Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15, with a Debt / Equity ratio of -0.28.
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Debt / Equity | -0.28 |
| Debt / EBITDA | -0.36 |
| Debt / FCF | -0.62 |
| Interest Coverage | -80.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-12.56M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -64.04% in the last 52 weeks. The beta is 1.41, so NRx Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.41 |
| 52-Week Price Change | -64.04% |
| 50-Day Moving Average | 2.45 |
| 200-Day Moving Average | 2.07 |
| Relative Strength Index (RSI) | 37.68 |
| Average Volume (20 Days) | 650.24K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -18.5M |
| Net Income | -25.13M |
| EBITDA | -18.5M |
| EBIT | -24.9M |
| Earnings Per Share (EPS) | -2.39 |
Balance Sheet
The company has 1.44M in cash and 6.58M in debt, giving a net cash position of -5.13M.
| Cash & Cash Equivalents | 1.44M |
| Total Debt | 6.58M |
| Net Cash | -5.13M |
| Retained Earnings | -278.27M |
| Total Assets | 3.65M |
| Working Capital | -18.56M |
Cash Flow
In the last 12 months, operating cash flow was -10.64M and capital expenditures 0, giving a free cash flow of -10.64M.
| Operating Cash Flow | -10.64M |
| Capital Expenditures | 0 |
| Free Cash Flow | -10.64M |
| FCF Per Share | -1.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NRXP is $31, which is 1557.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $31 |
| Price Target Difference | 1557.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Apr 2, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Apr 2, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -133.81 |
| Piotroski F-Score | 2 |